Search by Algolia
Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Olema Pharmaceuticals, Inc.Olema Pharmaceuticals Reports $43.8 Million Net Loss in Q2 2025
MYOMO, INC.Myomo Reports 28% Revenue Growth to $9.65 Million in Q2 2025, Despite Increased Net Loss
VIAVI SOLUTIONS INC.Viavi Solutions Reports $1.08 Billion Revenue, 8.4% Growth for Fiscal Year Ending June 28, 2025
Arcturus Therapeutics Holdings Inc.Arcturus Therapeutics Reports 43% Revenue Decline in Q2 2025
IRONWOOD PHARMACEUTICALS INCIronwood Pharmaceuticals Reports Q2 2025 Financial Results with $23.6M Net Income
Life360, Inc.Life360 Reports 36% Revenue Growth to $115.4 Million, Achieves Net Income of $7 Million
Tempest Therapeutics, Inc.Tempest Therapeutics Reports $7.87 Million Net Loss in Q2 2025, Initiates Cost-Reduction Measures
Armada Acquisition Corp. IIArmada Acquisition Corp. II Reports Net Income of $887,146 for Quarter Ending June 30, 2025
USA Rare Earth, Inc.USA Rare Earth Reports $91 Million Net Loss Amid Development Phase and Financing Activities
RCI HOSPITALITY HOLDINGS, INC.RCI Hospitality Holdings Reports $16.3M Net Income, Revenue Decline in Nine-Month Period
Kayne Anderson BDC, Inc.Kayne Anderson BDC Reports Financial Results for Quarter Ending June 30, 2025
Insight Molecular Diagnostics Inc.Insight Molecular Diagnostics Reports 398% Revenue Growth but Increased Net Loss in Latest Quarter
Septerna, Inc.Septerna Reports Revenue Decline and Increased Losses in Q2 2025
Exodus Movement, Inc.Exodus Movement Reports 16% Revenue Growth to $25.8 Million in Q2 2025
Repay Holdings CorpRepay Holdings Reports Q2 2025 Revenue of $75.6 Million, Net Loss of $102.3 Million
Sana Biotechnology, Inc.Sana Biotechnology Reports $93.8 Million Net Loss in Q2 2025, Adjusts Strategic Focus
Aquestive Therapeutics, Inc.Aquestive Therapeutics Reports 50% Revenue Decline in Q2 2025, Net Loss of $36.5 Million
KYNTRA BIO, INC.FibroGen Reports 35% Revenue Decline in Q2 2025, Plans Sale of Subsidiary to AstraZeneca
Atara Biotherapeutics, Inc.Atara Biotherapeutics Reports $40.4M Net Income for First Half of 2025, Faces Liquidity Concerns
Assertio Holdings, Inc.Assertio Holdings Reports Q2 2025 Revenue Decline and Increased Net Loss
FutureFuel Corp.FutureFuel Corp. Reports 51% Revenue Decline in Q2 2025, Faces Operational Challenges
Serina Therapeutics, Inc.Serina Therapeutics Reports Revenue Growth but Incurred $6.5 Million Loss in Q2 2025
Neurogene Inc.Neurogene Reports $22M Net Loss in Q2 2025, No Revenue Generated
Acurx Pharmaceuticals, Inc.Acurx Pharmaceuticals Reports Significant Reduction in Operating Expenses and Net Losses for Q2 2025
Fluence Energy, Inc.Fluence Energy Reports 25% Revenue Growth to $602.5 Million in Latest Quarter